Search results

Order by most recent / most popular / relevance

Results: 1-10 of 161

Supreme Court to Myriad: isolated DNA sequences are not patent-eligible subject matter

McDermott Will & Emery
-
USA
-
June 14 2013

The Supreme Court of the United States has released its highly anticipated decision in AMP et al. v. Myriad Genetics, Inc., et al., on the patenting

Osteoporosis patents found invalid

McDermott Will & Emery
-
USA
-
April 15 2013

Two osteoporosis treatment patents have been found to be invalid following the ruling by the High Court of England and Wales in Hospira UK Ltd & Anor

Federal Circuit affirms injunction against Impax labs and bars generic introduction

McDermott Will & Emery
-
USA
-
March 29 2013

Analyzing an injunction preventing a generic pharma house from introducing a new generic drug, the U.S. Court of Appeals for the Federal Circuit

Preliminary injunction upheld against misappropriated cardiovascular drug

McDermott Will & Emery
-
USA
-
March 29 2013

Finding sufficient evidence, the U.S. Court of Appeals for the Fifth Circuit affirmed a district court's preliminary injunction blocking the sale and

Supreme Court hears oral argument in pay-for-delay patent settlement antitrust case

McDermott Will & Emery
-
USA
-
March 26 2013

The Supreme Court's ruling in Federal Trade Commission v. Actavis, Inc., will almost certainly have major implications for the viability of Federal

Malaria combination patent invalidated for obviousness

McDermott Will & Emery
-
United Kingdom
-
March 13 2013

In Glenmark Generics (Europe) Limited & others v The Wellcome Foundation Limited & Glaxo Group Ltd 2013 EWHC 148 (Pat) the High Court has held that

Supreme Court limits availability of state action immunity from federal antitrust liability

McDermott Will & Emery
-
USA
-
February 20 2013

The Supreme Court decision in FTC v. Phoebe Putney Health System, Inc., makes clear that state action immunity from federal antitrust laws is

Generics challenge to Crestor patent fails

McDermott Will & Emery
-
USA
-
January 31 2013

In a case involving multiple defendants seeking to sell generic versions of the drug rosuvastatin calcium, currently marketed as Crestor, the U

Court of Appeal upholds invalidity of Alzheimer’s drug patent

McDermott Will & Emery
-
United Kingdom
-
January 9 2013

In Novartis AG v Generics (UK) Ltd (trading as Mylan) 2012 EWCA Civ 1623, the Court of Appeal has upheld the decision of the High Court that a patent

High Court of England and Wales has jurisdiction to try pan-European declaration of non-infringement action

McDermott Will & Emery
-
European Union, United Kingdom
-
January 9 2013

In Actavis Group HF v Eli Lilly and Company 2012 EWHC 3316 (Pat) the High Court of England and Wales has held that, in cases where there is no challenge

next >

Search results

Supreme Court to Myriad: isolated DNA sequences are not patent-eligible subject matter

Osteoporosis patents found invalid

Federal Circuit affirms injunction against Impax labs and bars generic introduction

Preliminary injunction upheld against misappropriated cardiovascular drug

Supreme Court hears oral argument in pay-for-delay patent settlement antitrust case

Malaria combination patent invalidated for obviousness

Supreme Court limits availability of state action immunity from federal antitrust liability

Generics challenge to Crestor patent fails

Court of Appeal upholds invalidity of Alzheimer’s drug patent

High Court of England and Wales has jurisdiction to try pan-European declaration of non-infringement action

Current Search

Suggested Facets

Author

Jurisdiction

Workarea